Keywords
SARS-CoV-2
vaccination
review
clinical trials
How to Cite
Abstract
SARS-CoV-2, the beta coronavirus causing COVID-19, was isolated and categorizes as a novel one on January 7th, 2020 in China.[1] To date, official reports depict that SARS-CoV-2 has already infected 88.828.387 persons and caused 1.926.625 deaths worldwide.[2] On January 12th, 2020, China officials made public its genetic sequence, thus paving the way towards the research and development of diagnostic tests and vaccines.
With regard to vaccination, e large number of clinical trials were designed and are currently undergoing, of which 189 are listed in ClinicalTrials.gov. [3] However, up to date, only three vaccines have published their respective phase III clinical trial results in peer-reviewed medical journals. [4-6]
Vaccines are needed to reduce the morbidity and mortality associated with Covid-19, and multiple vaccine platforms as AZD1222 (AstraZeneca) [4], BNT162b2 (Pfizer/BioNTech) [5] and mRNA-1273 (Moderna) have been involved in the rapid development of vaccine candidates.
Methodology: In this review, PubMed, Embase, Web of Science, Scopus, medRxiv, and bioRxiv were systematically scrutinized for peer-reviewed and preprint articles on phase III clinical trials of vaccines against SARS-CoV-2. In total, only three peer-reviewed papers fulfilling the search criteria were identified.
Conclusions; All vaccine candidates should publish in peer-reviewed journals their efficacy and safety well before requesting approval to the national or international authorities…
References
World Health Organization. Novel Coronavirus (2019-nCoV) Situation Report – 1. 21 January 2020. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200121-sitrep-1-2019-ncov.pdf
World Health Organization. Weekly Operational Update on COVID-19. 11 January 2020. https://www.who.int/publications/m/item/weekly-operational-update-on-covid-19---11-january-2021
https://clinicaltrials.gov/ct2/results?cond=%28covid-19+OR+Sars-Cov-2%29+AND+vaccine&term. Last accessed on January 12th, 2021.
Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. The Lancet 2021; 397; 10269: 99-111, December 08, 2020 https://doi.org/10.1016/S0140-6736(20)32661-1
Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med 2020; 383:2603-2615, December 10, 2020 doi: 10.1056/NEJMoa2034577
Baden LR, El Sahly HM, Essink B, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. December 30, 2020 doi: 10.1056/NEJMoa2035389
https://www.ema.europa.eu/en/news/ema-recommends-first-covid-19-vaccine-authorisation-eu. Last accessed on January 12th, 2021.
https://www.ema.europa.eu/en/news/ema-recommends-covid-19-vaccine-moderna-authorisation-eu. Last accessed on January 12th, 2021.
https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/pfizer-biontech-covid-19-vaccine. Last accessed on January 12th, 2021.
https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/moderna-covid-19-vaccine. Last accessed on January 12th, 2021.
https://www.astrazeneca.com/media-centre/press-releases/2020/astrazenecas-covid-19-vaccine-authorised-in-uk.html. Last accessed on January 12th, 2021.
https://www.evropaelire.org/a/shqiperi-vaksinimi-covid-19-/31041855.html. Last accessed on January 12th, 2021.
Pardi N, Tuyishime S, Muramatsu H, et al. Expression kinetics of nucleosidemodified mRNA delivered in lipid nanoparticles to mice by various routes. J Control Release 2015; 217: 345-51.
Karikó K, Muramatsu H, Welsh FA, et al. Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Mol Ther 2008; 16:1833-40.
Wrapp D, Wang N, Corbett KS, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 2020; 367: 1260-3.
Rare Diseases Database. https://rarediseases.org/rare-diseases/transverse-myelitis/ Last accessed on January 12th, 2021.
Istituto Superiore della Sanità Gruppo della Sorveglianza SARS-CoV-2, Palmieri L, Agazio E, Andrianou X, et al. Caratteristiche dei pazienti deceduti positivi all’infezione da SARS-CoV-2 in Italia. Rapporto December 16th 2020.
https://www.pharmacist.com/article/two-uk-suffer-allergic-reaction-pfizers-covid-19-vaccine. Last accessed on January 12th, 2021.
Submission of a manuscript implies that the submitted work has not been published before (except as part of a thesis or report, or abstract); that it is not under consideration for publication elsewhere; that its publication has been approved by all co-authors. If and when the manuscript is accepted for publication, the author(s) still hold the copyright and retain publishing rights without restrictions. Authors or others are allowed to multiply article as long as not for commercial purposes. For the new invention, authors are suggested to manage its patent before published. The license type is (CC BY-NC 4.0)